Brinas P, Chalret du Rieu M, Tuyeras G, Julio C H, Kirzin S, Ghouti L, Carrere N
Chirurgie générale et digestive, hôpital Purpan, CHU de Toulouse, place du Docteur-Baylac, 31059 Toulouse cedex 9, France.
Chirurgie générale et digestive, hôpital Purpan, CHU de Toulouse, place du Docteur-Baylac, 31059 Toulouse cedex 9, France.
J Visc Surg. 2018 Oct;155(5):355-363. doi: 10.1016/j.jviscsurg.2018.03.007. Epub 2018 Apr 7.
The indications for use of biological mesh prostheses are very limited because of their high cost, but include parietal repair in a contaminated setting. Their efficacy has been questioned by several recent studies. We therefore studied the results of all of our patients who received a biological prosthesis, including hernia recurrence and infectious complications.
We retrospectively reviewed the outcomes of 68 patients who underwent biological prosthesis placement from 2009 to 2015 in a single center.
The site of implantation was on the anterior abdominal wall in 49 (72%) of cases, in the pelvis in 19 (28%). The median follow-up was 19 months. In the early post-operative period, 22 (32.3%) of patients presented with wall abscess; eight (11.7%) underwent surgical revision and seven (10.2%) underwent interventional radiological drainage. In the medium term, 41/56 (73%) had a late complication; 32 (57%) of the patients developed recurrent herniation and 15 (26.7%) of them were re-operated. In addition, nine (16%) of patients developed a late surgical site infection and eight (14.2%) a chronic residual infection. In multivariate analysis, the risk factors for recurrence were parastomal hernia (P=0.007) and a history of recurrent hernia (P=0.002).
A majority of patients developed recurrent incisional herniation in the medium term. This puts the use of biological prostheses into question. These results need to be compared to those of semi-absorbable prostheses.
生物网片假体由于成本高昂,其使用指征非常有限,但包括在污染环境中的腹壁修补。最近的几项研究对其疗效提出了质疑。因此,我们研究了所有接受生物假体的患者的结果,包括疝复发和感染并发症。
我们回顾性分析了2009年至2015年在单一中心接受生物假体植入的68例患者的结局。
植入部位在腹壁前部的有49例(72%),在骨盆的有19例(28%)。中位随访时间为19个月。术后早期,22例(32.3%)患者出现腹壁脓肿;8例(11.7%)接受了手术翻修,7例(10.2%)接受了介入放射引流。中期,56例中有41例(73%)出现晚期并发症;32例(57%)患者出现复发性疝,其中15例(26.7%)再次手术。此外,9例(16%)患者出现晚期手术部位感染,8例(14.2%)出现慢性残余感染。多因素分析显示,复发的危险因素是造口旁疝(P=0.007)和复发性疝病史(P=0.002)。
大多数患者在中期出现复发性切口疝。这使生物假体的使用受到质疑。这些结果需要与半可吸收假体的结果进行比较。